Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497515 | 1.00 | ALOX15 (0.34) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| SCHEMBL8229593 | 0.84 | LDHA (0.42) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| SCHEMBL10440768 | 0.74 | ALOX15 (0.39) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| SCHEMBL17975858 | 0.71 | ALOX15 (0.40) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| Acetic Acid SCHEMBL10534954 | 0.71 | ALDH1A1 (0.45) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| Acetic Acid SCHEMBL1816061 | 0.71 | ALDH1A1 (0.45) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| Acetone SCHEMBL7158493 | 0.71 | ALDH1A1 (0.45) | ALOX15HSD17B10LDHASRRALDH1A1 | |
| SCHEMBL362181 | 0.70 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL6647502 | 0.69 | LDHA (0.57) | LDHASRRALDH1A1TSHR | |
| SCHEMBL6647501 | 0.69 | LDHA (0.57) | LDHASRRALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | SCHERING AG (DE) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | AR, FSHR, GNRHR | ALOX15 2495/4885HSD17B10 648/4885LDHA 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.